Viking Therapeutics (VKTX) is highlighted as a stock to watch, with its ongoing phase 3 trials for lead drug VK2735 cited as the key catalyst for shareholder value. The article notes the drug showed impressive results in a phase 2 trial, though no specific figures were disclosed. The piece frames VKTX as a preferred buy candidate in the event of a broader market crash.
Viking Therapeutics Cited as Stock to Watch, With Phase 3 Trials Seen as Key Value Driver
Viking Therapeutics (VKTX) is being highlighted as a stock to watch, with its ongoing phase 3 trials described as the key to unlocking value for shareholders.
Lead Drug VK2735
The company’s lead drug, VK2735, has demonstrated impressive results in a phase 2 trial, according to the source article. No specific figures from that trial were disclosed.
Phase 3 as the Catalyst
The article frames the ongoing phase 3 trials as the central catalyst for shareholder value, positioning the trial progress as the factor investors should monitor.
Framing in a Market Downturn
The piece presents VKTX as the stock the author would most want to buy in the event of a broader market crash, framing it as a preferred buy candidate under those conditions.
The source article was published by fool.com on November 5, 2026.